A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY INVESTIGATING THE EFFICACY AND SAFETY OF BUROSUMAB, AN ANTI-FGF23 ANTIBODY, IN ADULT X-LINKED HYPOPHOSPHATEMIA (XLH)
2018
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
1
Citations
NaN
KQI